Da J. Fu

Shanghai, 200025, China

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 149 publications

Mechanisms of synergistic action between olaparib and KPT-330 in pancreatic cancer.

Mechanisms of synergistic action between olaparib and KPT-330 in pancreatic cancer.

Journal: Cell biology and toxicology

Published: January 28, 2026

Fundamentals and emerging frontiers in p53-targeted drug development.

Fundamentals and emerging frontiers in p53-targeted drug development.

Journal: Biochemistry and biophysics reports

Published: December 25, 2025

Regulation of tumorigenesis by cellular senescence: Mechanisms and pathways in liver cancer and cholangiocarcinoma.

Regulation of tumorigenesis by cellular senescence: Mechanisms and pathways in liver cancer and cholangiocarcinoma.

Journal: Biochimica et biophysica acta. Reviews on cancer

Published: December 24, 2025

Defactinib inhibits focal adhesion kinase to attenuate pancreatic cancer growth via PI3K/AKT pathway modulation.

Defactinib inhibits focal adhesion kinase to attenuate pancreatic cancer growth via PI3K/AKT pathway modulation.

Journal: Biochimica et biophysica acta. Molecular basis of disease

Published: December 09, 2025

LLPS-based classification and a novel prognostic signature reveal NRF1 as a therapeutic target in pancreatic cancer.

LLPS-based classification and a novel prognostic signature reveal NRF1 as a therapeutic target in pancreatic cancer.

Journal: Cancer cell international

Published: August 23, 2025

TMEM158-mediated TGF-β signaling pathway modulates the sensitivity of TP53-deficient osteosarcoma to USP14 inhibitors.

TMEM158-mediated TGF-β signaling pathway modulates the sensitivity of TP53-deficient osteosarcoma to USP14 inhibitors.

Journal: Molecular and cellular biochemistry

Published: July 08, 2025

Current status and future prospects of immunotherapy for pancreatic ductal adenocarcinoma.

Current status and future prospects of immunotherapy for pancreatic ductal adenocarcinoma.

Journal: Journal of cancer research and therapeutics

Published: June 04, 2025

Integrated multiomics analysis identifies PHLDA1+ fibroblasts as prognostic biomarkers and mediators of biological functions in pancreatic cancer.

Integrated multiomics analysis identifies PHLDA1+ fibroblasts as prognostic biomarkers and mediators of biological functions in pancreatic cancer.

Journal: Frontiers in immunology

Published: March 12, 2025

FNDC4 Drives Metastasis and Immune Evasion in Pancreatic Cancer.

FNDC4 Drives Metastasis and Immune Evasion in Pancreatic Cancer.

Journal: Cancer research

Published: March 05, 2025

The complex interplay between diabetes mellitus and pancreatic carcinogenesis: deciphering multifactorial mechanisms and identifying emerging therapeutic vulnerabilities.

The complex interplay between diabetes mellitus and pancreatic carcinogenesis: deciphering multifactorial mechanisms and identifying emerging therapeutic vulnerabilities.

Journal: Cell & bioscience

Published: February 06, 2025

RBM10 inhibits pancreatic cancer development by suppressing immune escape through PD-1 expression.

RBM10 inhibits pancreatic cancer development by suppressing immune escape through PD-1 expression.

Journal: Journal of Cancer

Published: February 03, 2025

Development of a prognostic model based on m6A reader HNRNPA2B1 upregulation and immune infiltration in multiple malignant tumors.

Development of a prognostic model based on m6A reader HNRNPA2B1 upregulation and immune infiltration in multiple malignant tumors.

Journal: Translational cancer research

Published: December 23, 2024

Showing 1-12 of 149

Last Updated: 09/26/2026